You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 17, 2025

Drug Sales Trends for JUNEL 1/20


✉ Email this page to a colleague

« Back to Dashboard


Payment Methods and Pharmacy Types for JUNEL 1/20 (2021)

Revenues by Pharmacy Type

Pharmacy Type Revenues
INSIDE ANOTHER STORE $1,404,300
INSIDE HMO/CLINIC/HOSPITAL $3,310,070
[disabled in preview] $22,355,833
This preview shows a limited data set
Subscribe for full access, or try a Trial

Units Sold by Pharmacy Type

Pharmacy Type Units
INSIDE ANOTHER STORE 40,828
INSIDE HMO/CLINIC/HOSPITAL 45,175
[disabled in preview] 602,194
This preview shows a limited data set
Subscribe for full access, or try a Trial

Revenues by Payment Method

Payment Method Revenues
MEDICAID $777,713
PRIVATE INSURANCE $22,501,500
[disabled in preview] $3,790,990
This preview shows a limited data set
Subscribe for full access, or try a Trial
Drug Sales Revenue Trends for JUNEL 1/20
Drug Units Sold Trends for JUNEL 1/20

Market Analysis and Sales Projections for Junel Fe 1/20

Introduction to Junel Fe 1/20

Junel Fe 1/20 is a combination birth control pill that contains norethindrone acetate and ethinyl estradiol, along with ferrous fumarate tablets to facilitate a 28-day regimen. This medication is designed to prevent pregnancy, lighten and regularize menstrual periods, reduce menstrual pain, and treat hormone-based acne[2][5].

Market Context: Contraceptive Drugs

The global contraceptive drugs market has been growing steadily, driven by increasing concerns about family planning and the need to prevent unintended pregnancies. In 2019, the market size was valued at $14,324.12 million and is projected to reach $24,412.22 million by 2027, with a Compound Annual Growth Rate (CAGR) of 6.9% during the forecast period. This growth is fueled by higher educational attainment, increased awareness of modern contraception methods, and the rising use of oral pills among young women[3].

Target Demographics

Junel Fe 1/20 is primarily targeted at women of childbearing age, typically between 15 and 44 years old. This demographic is increasingly seeking effective and convenient methods of birth control, which aligns with the benefits offered by Junel Fe 1/20, such as lighter and more regular periods, reduced menstrual pain, and acne treatment[2][3].

User Experience and Reviews

User reviews of Junel Fe 1/20 are mixed. On Drugs.com, the medication has an average rating of 4.4 out of 10 from 838 reviews, with 28% of reviewers reporting a positive experience and 52% reporting a negative experience. Common positive outcomes include lighter periods and reduced cramps, while negative experiences often involve severe anxiety, depression, and unpredictable bleeding[1].

Pharmacokinetics and Safety Considerations

Junel Fe 1/20 has a well-defined pharmacokinetic profile, with an absolute bioavailability of approximately 64% for norethindrone and 43% for ethinyl estradiol. The medication is primarily metabolized in the liver and excreted through both renal and fecal routes. However, patients with hepatic impairment may poorly metabolize the components of Junel Fe 1/20, which could impact its efficacy and safety[4][5].

Market Competitiveness

The contraceptive drugs market is highly competitive, with various types of contraceptives available, including oral pills, injectable contraceptives, and topical contraceptives. Junel Fe 1/20 competes with other combination birth control pills that offer similar benefits. The market competitiveness is also influenced by factors such as insurance coverage, out-of-pocket costs, and the availability of alternative contraceptive methods[3].

Pricing and Accessibility

The pricing of Junel Fe 1/20 can vary depending on insurance coverage and the pharmacy. For example, through services like Nurx, the medication can cost as little as $0 per month with insurance or $15 per month out-of-pocket, plus a consultation fee. This accessibility makes Junel Fe 1/20 a viable option for many women seeking affordable birth control[2].

Sales Projections

Given the growing demand for contraceptive drugs and the specific benefits of Junel Fe 1/20, sales projections are likely to be positive. Here are some key points to consider:

  • Market Growth: The overall contraceptive drugs market is expected to grow at a CAGR of 6.9% until 2027, which suggests a favorable environment for Junel Fe 1/20.
  • User Demand: Despite mixed user reviews, the medication addresses significant needs such as lighter periods, reduced menstrual pain, and acne treatment, which will continue to drive demand.
  • Competitive Positioning: Junel Fe 1/20’s low dose of estrogen and additional benefits like acne treatment position it well in the market, especially for women seeking a comprehensive birth control solution.

Challenges and Opportunities

Challenges

  • Side Effects: Severe side effects such as anxiety, depression, and unpredictable bleeding reported by some users could impact sales and user satisfaction.
  • Health Risks: Health risks associated with the use of contraceptives, including those related to hepatic and renal impairments, need to be carefully managed and communicated to potential users.
  • Alternative Methods: The availability of alternative contraceptive methods could divert some users away from Junel Fe 1/20.

Opportunities

  • Increasing Awareness: Growing awareness about modern contraception methods and the importance of family planning can increase demand for Junel Fe 1/20.
  • Online Health Services: The rise of online health services like Nurx, which offer convenient and affordable access to birth control, can significantly boost sales of Junel Fe 1/20.
  • Continuous Improvement: Addressing user concerns and continuously improving the formulation and delivery of Junel Fe 1/20 can enhance user satisfaction and loyalty.

Key Takeaways

  • Junel Fe 1/20 is a combination birth control pill with a low dose of estrogen, designed to prevent pregnancy, lighten periods, reduce menstrual pain, and treat acne.
  • The global contraceptive drugs market is growing, driven by increasing concerns about family planning and the need to prevent unintended pregnancies.
  • User reviews are mixed, highlighting both positive outcomes and significant side effects.
  • The medication faces competition in the market but is well-positioned due to its comprehensive benefits and affordable pricing.
  • Sales projections are positive, driven by market growth, user demand, and the rise of online health services.

FAQs

Q: What are the primary benefits of Junel Fe 1/20? A: Junel Fe 1/20 helps prevent pregnancy, lightens and regularizes menstrual periods, reduces menstrual pain, and treats hormone-based acne.

Q: What are the common side effects reported by users of Junel Fe 1/20? A: Common side effects include severe anxiety, depression, unpredictable bleeding, and in some cases, suicidal thoughts.

Q: How does Junel Fe 1/20 compare to other birth control pills in terms of pricing? A: Junel Fe 1/20 can be as affordable as $0 per month with insurance or $15 per month out-of-pocket, making it a competitive option in the market.

Q: What demographic is Junel Fe 1/20 primarily targeted at? A: Junel Fe 1/20 is targeted at women of childbearing age, typically between 15 and 44 years old.

Q: How does the global contraceptive drugs market impact the sales of Junel Fe 1/20? A: The growing global contraceptive drugs market, driven by increasing concerns about family planning and the need to prevent unintended pregnancies, creates a favorable environment for the sales of Junel Fe 1/20.

Cited Sources

  1. Drugs.com - Junel Fe 1/20 User Reviews & Ratings
  2. Nurx - Junel Fe 1/20 (Loestrin Fe)
  3. Allied Market Research - Contraceptive Drugs Market Size, Share | Statistics - 2035
  4. eMPR.com - JUNEL Fe 1/20 Prescription & Dosage Information
  5. DailyMed - Label: JUNEL FE 1/20- norethindrone acetate and ethinyl estradiol, and ferrous fumarate kit
Last updated: 2025-01-03

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.